ReviewGlobal health, epidemiology and genomics2025
Genomic Evolution and Epidemiological Impact of Ongoing Clade Ib MPox Disease: A Narrative Review.
Review in Global health, epidemiology and genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of mpox infection among men who have sex with men: a systematic review and meta-analysis.Infectious diseases of poverty · 2026Pooled it
- Differential pathogenesis and antiviral treatment outcomes of MPXV clade Ib and clade IIb in a BALB/c mouse model.Emerging microbes & infections · 2026Article
- Viral Metagenomic Next-Generation Sequencing for One Health Discovery and Surveillance of (Re)Emerging Viruses: A Deep Review.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clade 1b of the MPox virus has emerged as a highly virulent strain, causing significant public health challenges globally. Initially endemic to Central Africa, this strain has spread to nonendemic regions, including Europe, Asia, and the Americas. With its high transmission rate and severe outcomes, especially among vulnerable populations like children, Clade 1b has raised global concerns. The Africa Center for Disease Control and Prevention (CDC) has declared it a public health emergency of international concern. Clade 1b MPox shows a higher case fatality rate and increased transmissibility compared to other strains. It has moved beyond traditional zoonotic transmission to widespread human-to-human transmission. The variant's spread to countries such as Sweden and Thailand demonstrates its global reach. Public health efforts, including cross-border coordination, rapid response teams, and awareness campaigns, have been essential in containing the outbreaks. However, barriers such as limited resources, vaccine shortages, and logistical challenges in conflict-affected areas have hindered effective control, particularly in low-resource regions. The spread and severity of Clade 1b MPox highlight the need for global cooperation to strengthen surveillance, improve diagnostic capabilities, and expand healthcare infrastructure in affected areas. Enhancing access to vaccines and treatments, along with educating the public on preventive measures, will be key to controlling transmission. Ongoing research and monitoring are essential to mitigate future outbreaks and minimize the virus's global impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.